LEIDEN, Netherlands, April 15 (UPI) -- Dutch biotech company Crucell N.V. said it has signed a contract with the Vaccine Research Center to make Ebola vaccine material.
The contract with the NIH's National Institute of Allergy and Infectious Diseases calls for Crucell to manufacture up to 10 batches of clinical material of the PER.C6-based Ebola vaccine. The materials will be used for Phase I and early Phase II clinical studies in humans.
Crucell will receive up to $27.6 million from the NIH for the clinical lots.
Crucell has focused research on developing vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria, West Nile virus and rabies.
The company's development programs include collaborations with Sanofi Pasteur for influenza vaccines, the NIH for Ebola and malaria vaccines, and GlaxoSmithKline, Walter Reed Army Institute of Research and New York University for a malaria vaccine.
